Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health Inc. (OTCQB: ODYY) is a medical company focused on life-saving and life-enhancing medical solutions, and its news flow reflects this emphasis on critical care and diagnostic technologies. Company announcements highlight development milestones, licensing transactions, financing arrangements and strategic asset sales that shape its evolving portfolio.
Recent news has detailed Odyssey’s entry into the breast cancer diagnostics marketplace through a Master Technology and Sub-license Agreement for exclusive, worldwide rights to BreastCheck ae, a non-invasive test for breast abnormalities. Press releases describe BreastCheck ae as a home-use, temperature-based screening tool that provides results in about 15 minutes and is intended to complement established diagnostic procedures. Updates also cover regulatory status, including FDA registration in the United States and registrations with authorities in the European Union and the United Kingdom.
Odyssey’s news archive also covers progress on its Save A Life choking rescue device, a patented vacuum-based system designed to dislodge airway obstructions rapidly. The company has reported creating a prototype and planning further development with the goal of an FDA submission, illustrating how it communicates development stages and regulatory intentions to investors and stakeholders.
Another key theme in Odyssey’s news is corporate and financial strategy. Releases describe the sale of its neurological drug technology pipeline, including the concussion candidate ONP-002, to Oragenics, Inc., as well as the resulting investment in Oragenics preferred stock. Additional coverage explains long-term service contracts and financing facilities, such as the multi-year maintenance service agreement and related funding capacity with Mast Hill Fund, L.P., which the company characterizes as supporting its transition toward recurring revenue and commercialization initiatives.
Investors and observers can use the ODYY news page on Stock Titan to follow these developments, including device development updates, licensing agreements, regulatory steps, financing transactions and portfolio changes that may influence Odyssey Health’s business trajectory.
Odyssey Group International, Inc. (OTCQB:ODYY) has announced the successful completion of the design development phase of its Save A Life choking rescue device, in collaboration with Tanaka Kapec Design Group. The product is now transitioning to the prototyping stage, where experts will test and refine its effectiveness. The collaboration has optimized the device's design for enhanced ergonomics and usability. CEO Michael Redmond expressed enthusiasm for advancing towards FDA submission to improve outcomes for choking emergencies.
Odyssey Group International, Inc. (OTCQB:ODYY) and Prevacus Inc. announced positive pre-clinical results for PRV-002, a nasal drug aimed at treating concussions. The studies indicated that PRV-002 demonstrated rapid brain absorption, with enhanced bioavailability when formulated as nanoparticles. After nasal administration, approximately 40% more of the drug was detected in brain tissues after 8 hours compared to its native form. Odyssey is set to finalize its acquisition of PRV-002 by the end of February, contingent on shareholder approval.
Odyssey Group International, Inc. (OTCQB: ODYY) announced significant media coverage for its concussion treatment, Prevasol. Recent appearances include CheddarTV on February 5, Newsmax on February 7, and Fox Business on February 8, featuring CEO Dr. Jake VanLandingham and former NFL stars discussing brain injuries. The company is excited about its pending partnership with Prevacus, with a definitive agreement to acquire the drug candidate PRV-002 expected to close by the end of February 2021, pending shareholder approval.
Odyssey Group International, Inc. (OTCQB: ODYY) has announced significant advancements in its product development for the fiscal year ending July 31, 2020. Key highlights include the continued development of the Save a Life® choking rescue device and the initiation of the CardioMap® device aimed at heart disease diagnostics. The company appointed Mike Contarino to lead product development and established a partnership with Majic LLC for manufacturing quality assurance. Financial backing is secured from Lincoln Park Capital as Odyssey prepares for FDA submissions and plans international distribution.